PTGS2 and Familial prostate cancer: Clinical trials using COX-2 inhibitors in patients with biochemical recurrence of prostate cancer have suggested that COX-2 inhibition may improve survival [8,9], and pre-clinical studies with cell lines and animal models have established a functional link between COX-2 expression and an aggressive cancer phenotype.